Can­cer R&D tips the scales at the FDA as ac­tive INDs climb to record high

The FDA pe­ri­od­i­cal­ly likes to give it­self a high grade as a top per­former. And like any good bu­reau­cra­cy, it has the num­bers to back it­self up. But a new pre­sen­ta­tion by Patrick Frey, the chief of staff in the Of­fice of New Drugs at the agency, has come up with a se­ries of slides that al­so un­der­scores some im­por­tant trends in drug R&D.

One of the top snap­shots in the slide show high­lights a key fact. As of the end of No­vem­ber, ac­tive INDs hit 7,020 — and that’s a 14-year high sig­ni­fy­ing a steady growth since 2004, when the num­ber was 4,361.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.